comprehensive -WSS

comprehensive

author：comprehensive 2025-08-07 04:33:57 - browse：977

Boston Globe

A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and pediatricians to scramble for alternatives just as allergy season is about to start.

In a move unusual for such a widely used drug, GlaxoSmithKline discontinued Flovent HFA, the brand name of its corticosteroid treatment fluticasone propionate, at the end of December. Critics, including Massachusetts Senator Elizabeth Warren, say the decision helps the company avoid new Medicaid penalties going into effect this year for medications with price increases that outpace inflation.

“It was all very confusing, and we were left scrambling, trying to find out what we could do,” said Simone Fung, whose 5-year-old son, David, endured worse asthma symptoms over the past two months as the Cambridge family navigated confusing insurance policies and shortages of alternative medications to find a replacement for Flovent.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Congress must reauthorize a committee to support older Americans

leisure time

WSS

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Decaf coffee targeted by food safety group under obscure FDA rule

Food as medicine: Medically tailored meals may get standardized

focus

comprehensive

entertainment

Medical leaders decry Supreme Court decision on affirmative action

A daunting task: navigating dual Medicare, Medicaid eligibility

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Readout: Lenmeldy, GLP

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Tori Bowie and the unacceptable rates of Black maternal death

Congress must reauthorize a committee to support older Americans

The cancer drug shortage isn’t new — and neither are the solutions

Covid vaccine financial winners and losers, from Pfizer to Novavax

leisure time

A daunting task: navigating dual Medicare, Medicaid eligibility

CRISPR pioneers react to Casgevy, first gene

Hospitals look to new technology to keep health care workers safe

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

There's no autism epidemic. It's an autism diagnosis epidemic

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

leisure time

focus

knowledge

explore